Literature DB >> 6282759

Monoclonal antibodies of four different specificities for neutralization of type 1 polioviruses.

D D Humphrey, O M Kew, P M Feorino.   

Abstract

Four independent hybridoma clones have been established that produce neutralizing antibodies specific to type 1 poliovirus. Each clone produced antibody which neutralized a distinct set of type 1 test strains: (i) all 15 strains tested; (ii) the inducer strain only; (iii) predominantly wild strains; or (iv) all vaccine-related and some wild strains.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6282759      PMCID： PMC351306          DOI： 10.1128/iai.36.2.841-843.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  8 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  The use of a modified Wecker technique for the serodifferentiation of type 1 polioviruses related and unrelated to Sabin's vaccine strain. I. Standardization and evaluation of the test.

Authors:  J H NAKANO; H M GELFAND
Journal:  Am J Hyg       Date:  1962-05

3.  Changes in three of the four coat proteins of oral polio vaccine strain derived from type 1 poliovirus.

Authors:  O M Kew; M A Pallansch; D R Omilianowski; R R Rueckert
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

4.  Production of monoclonal antibodies against nucleocapsid proteins of herpes simplex virus types 1 and 2.

Authors:  M Zweig; C J Heilman; H Rabin; R F Hopkins; R H Neubauer; B Hampar
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

5.  Complement-fixing antigens produced by varicella-zoster virus in tissue culture.

Authors:  M L Martin; E L Palmer
Journal:  Appl Microbiol       Date:  1973-09

6.  Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein.

Authors:  A Flamand; T J Wiktor; H Koprowski
Journal:  J Gen Virol       Date:  1980-05       Impact factor: 3.891

7.  Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans.

Authors:  B K Nottay; O M Kew; M H Hatch; J T Heyward; J F Obijeski
Journal:  Virology       Date:  1981-01-30       Impact factor: 3.616

8.  Epidemiological implications of the isolations and intratypic serodifferentiation of poliovirus strains in the Netherlands.

Authors:  J G Kapsenberg; R A Coutinho; A G Hazendonk; A B Ran; A L van Wezel
Journal:  Dev Biol Stand       Date:  1981
  8 in total
  10 in total

1.  Structural analysis of hepatitis B surface antigen by monoclonal antibodies.

Authors:  E Ben-Porath; J R Wands; R A Marciniak; M A Wong; L Hornstein; R Ryder; M Canlas; A Lingao; K J Isselbacher
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

2.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

3.  A new epidemiologic and laboratory classification system for paralytic poliomyelitis cases.

Authors:  R W Sutter; E W Brink; S L Cochi; O M Kew; W A Orenstein; R J Biellik; A R Hinman
Journal:  Am J Public Health       Date:  1989-04       Impact factor: 9.308

4.  Intertypic cross-reactions of nonneutralizing, monoclonal poliovirus antibodies.

Authors:  R Vrijsen; B Rombaut; A Boeye
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies.

Authors:  E A Emini; S Y Kao; A J Lewis; R Crainic; E Wimmer
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

6.  Application of a solid-phase immunofluorometric assay to the selection of monoclonal antibody specific for the adenovirus group-reactive hexon antigen.

Authors:  J C Hierholzer; D J Phillips; D D Humphrey; R A Coombs; C B Reimer
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

7.  Natural variation of poliovirus neutralization epitopes.

Authors:  R Crainic; P Couillin; B Blondel; N Cabau; A Boué; F Horodniceanu
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

8.  Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment.

Authors:  B Baxt; D O Morgan; B H Robertson; C A Timpone
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

9.  Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.

Authors:  A Sădziene; P A Rosa; P A Thompson; D M Hogan; A G Barbour
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

Review 10.  The application of monoclonal antibodies in the study of viruses.

Authors:  M J Carter; V ter Meulen
Journal:  Adv Virus Res       Date:  1984       Impact factor: 9.937
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.